Treatment of IDH-mutant glioma in the INDIGO era

Gliomas are the most common primary brain tumor and are uniformly lethal. Despite significant advancements in understanding the genetic landscape of gliomas, standard-of-care has remained largely unchanged. Subsets of gliomas are defined by gain-of-function mutations in the metabolic genes encoding...

Full description

Saved in:
Bibliographic Details
Published in:NPJ precision oncology 2024-07, Vol.8 (1), p.149-7, Article 149
Main Authors: Lin, Mathew D., Tsai, Alexander C.-Y., Abdullah, Kalil G., McBrayer, Samuel K., Shi, Diana D.
Format: Article
Language:English
Subjects:
631/67/1922
692/699/67/1922
Adjuvants
Brain cancer
Brain research
Cancer Research
Cancer therapies
Chemotherapy
Dehydrogenases
Enzymes
Gene Therapy
Glioma
Human Genetics
Internal Medicine
Medicine
Medicine & Public Health
Metabolism
Mutation
Oncology
Radiation
Review Article
Surgery
Toxicity
Tumors
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Gliomas are the most common primary brain tumor and are uniformly lethal. Despite significant advancements in understanding the genetic landscape of gliomas, standard-of-care has remained largely unchanged. Subsets of gliomas are defined by gain-of-function mutations in the metabolic genes encoding isocitrate dehydrogenase (IDH). Efforts to exploit mutant IDH activity and/or directly inhibit it with mutant IDH inhibitors have been the focus of over a decade of research. The recently published INDIGO trial, demonstrating the benefit of the mutant IDH inhibitor vorasidenib in patients with low-grade IDH-mutant gliomas, introduces a new era of precision medicine in brain tumors that is poised to change standard-of-care. In this review, we highlight and contextualize the results of the INDIGO trial and introduce key questions whose answers will guide how mutant IDH inhibitors may be used in the clinic. We discuss possible combination therapies with mutant IDH inhibition and future directions for clinical and translational research.
ISSN:2397-768X
2397-768X
DOI:10.1038/s41698-024-00646-2